News | November 12, 2024
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Read More
News | November 11, 2024
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
Read More
News | November 7, 2024
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations November 07, 2024 08:30 ET | Source: Palvella Therapeutics
Read More
News | October 24, 2024
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Read More
